Bristol-Myers Squibb Company

news

Bristol-Myers Squibb and Pfizer announce enrollment of first patient in Phase IV EMANATE trial to assess effectiveness and safety of Eliquis® (apixaban) in patients with NVAF undergoing cardioversion

18 July 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Pfizer Inc. announced that the first patient has been enrolled into a Phase IV clinical trial called EMANATE assessing the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation undergoing cardioversion...

news

Bristol-Myers Squibb announces plans for third quarter submission of a biologics license application for opdivo® (nivolumab)

11 July 2014 | By Bristol-Myers Squibb

...an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma...

news

Japan approves first all-oral, interferon- and ribavirin-free hepatitis C treatment, daklinza® (daclatasvir) and sunvepra® (asunaprevir) dual regimen

7 July 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare has approved Daklinza® (daclatasvir)...

news

Phase 3 first-line melanoma study of Nivolumab, an investigational PD-1 checkpoint inhibitor, demonstrates superior overall survival compared to Dacarbazine; study stopped early

25 June 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma was stopped early...

news

Bristol-Myers Squibb announces dividend

18 June 2014 | By Bristol-Myers Squibb

The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-six cents per share on the $.10 par value Common Stock of the corporation...

news

AVERT trial demonstrates high rates of DAS-defined remission with Orencia® (abatacept) in combination with Methotrexate in adult patients with early rheumatoid arthritis

11 June 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...

news

Giovanni Caforio, M.D., appointed Chief Operating Officer and elected to Board of Directors

9 June 2014 | By European Pharmaceutical Review

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Giovanni Caforio, M.D., has been appointed chief operating officer and elected to Bristol-Myers Squibb’s Board of Directors, effective June 5, 2014. He will continue to report to Lamberto Andreotti, chief executive officer. In addition to his current responsibilities as chief commercial officer, Caforio…

news

One- & two-year survival rates of 94% and 88% announced from Phase 1b trial of investigational PD-1 checkpoint inhibitor nivolumab and yervoy® (ipilimumab) in advanced melanoma

3 June 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...

news

Bristol-Myers Squibb and Incyte enter clinical collaboration agreement to evaluate combination regimen of two novel immunotherapies

28 May 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...

news

Bristol-Myers Squibb to present new remission data on ORENCIA® (abatacept) and Clazakizumab at The European League Against Rheumatism 2014 Annual Meeting

21 May 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that 20 abstracts for Orencia® (abatacept), and clazakizumab have been accepted for presentation at the 2014 annual meeting of the European League Against Rheumatism...

news

Bristol-Myers Squibb and AbbVie receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an investigational humanized monoclonal antibody for multiple myeloma

20 May 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company and AbbVie announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone...

news

Bristol-Myers Squibb announces Retirement of Brian Daniels

7 May 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that Brian Daniels, senior vice president, Global Development and Medical Affairs, will be retiring from the company...

news

Bristol-Myers Squibb continues to lead the advancement of immuno-oncology with broad set of new data at 2014 American Society of Clinical Oncology Annual Meeting

6 May 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology...

news

Bristol-Myers Squibb and Samsung BioLogics expand manufacturing agreement

23 April 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...

news

Bristol-Myers Squibb submits new drug application to FDA for a fixed-dose combination of atazanavir sulfate with cobicistat for HIV-1

14 April 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced the submission of a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate...